Michael C. Campbell to Structure-Activity Relationship
This is a "connection" page, showing publications Michael C. Campbell has written about Structure-Activity Relationship.
Connection Strength
0.314
-
Liu W, Mousa AAK, Dayer G, Hopkins AM, Campbell M, Mao Y, Jiang ZH, Lees SJ, Ramachandran R, Hou J. Urea-based lysophosphatidic acid receptor 1 antagonists as potential migrastatics for triple-negative breast cancer. Bioorg Chem. 2026 07 05; 175:109807.
Score: 0.053
-
Leas DA, H?berli C, White KL, Shackleford DM, Jones JO, Campbell M, Wu J, Kaushik D, Dong Y, Wallick AI, Charman SA, Keiser J, Davis PH, Vennerstrom JL. Structure-Activity Relationship of Antischistosomal Aryl Hydantoin (AR102). J Med Chem. 2025 Oct 23; 68(20):21725-21738.
Score: 0.052
-
Nie Z, Bonnert R, Tsien J, Deng X, Higgs C, El Mazouni F, Zhang X, Li R, Ho N, Feher V, Paulsen J, Shackleford DM, Katneni K, Chen G, Ng ACF, McInerney M, Wang W, Saunders J, Collins D, Yan D, Li P, Campbell M, Patil R, Ghoshal A, Mondal P, Kundu A, Chittimalla R, Mahadeva M, Kokkonda S, White J, Das R, Mukherjee P, Angulo-Barturen I, Jim?nez-D?az MB, Malmstrom R, Lawrenz M, Rodriguez-Granillo A, Rathod PK, Tomchick DR, Palmer MJ, Laleu B, Qin T, Charman SA, Phillips MA. Structure-Based Discovery and Development of Highly Potent Dihydroorotate Dehydrogenase Inhibitors for Malaria Chemoprevention. J Med Chem. 2025 01 09; 68(1):590-637.
Score: 0.049
-
Leas DA, Keiser J, Charman SA, Shackleford DM, Jones JO, Campbell M, Chen G, Katneni K, Patil R, Hu M, Pham T, H?berli C, Schulze TT, Neville AJ, Wang X, Dong Y, Davis PH, Vennerstrom JL. Single-Dose Drug Development Candidate for Schistosomiasis. ACS Infect Dis. 2024 11 08; 10(11):3963-3972.
Score: 0.048
-
Liu W, Mousa AAK, Hopkins AM, Wu YF, Thu KL, Campbell M, Lees SJ, Ramachandran R, Hou J. Lysophosphatidic Acid Receptor 1 (LPA1) Antagonists as Potential Migrastatics for Triple Negative Breast Cancer. ChemMedChem. 2024 Aug 19; 19(16):e202400013.
Score: 0.047
-
Weaver MJ, Stump S, Campbell MJ, Backos DS, Li C, Reigan P, Adams E, Beall HD, Natale NR. 10-N-heterocylic aryl-isoxazole-amides (AIMs) have robust anti-tumor activity against breast and brain cancer cell lines and useful fluorescence properties. Bioorg Med Chem. 2020 11 15; 28(22):115781.
Score: 0.037
-
Phillips MA, White KL, Kokkonda S, Deng X, White J, El Mazouni F, Marsh K, Tomchick DR, Manjalanagara K, Rudra KR, Wirjanata G, Noviyanti R, Price RN, Marfurt J, Shackleford DM, Chiu FC, Campbell M, Jimenez-Diaz MB, Bazaga SF, Angulo-Barturen I, Martinez MS, Lafuente-Monasterio M, Kaminsky W, Silue K, Zeeman AM, Kocken C, Leroy D, Blasco B, Rossignol E, Rueckle T, Matthews D, Burrows JN, Waterson D, Palmer MJ, Rathod PK, Charman SA. A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria. ACS Infect Dis. 2016 12 09; 2(12):945-957.
Score: 0.028